On August 1 2023, Vertex Pharmaceuticals ($NASDAQ:VRTX) announced total revenue of USD 2493.2 million and net income of USD 915.7 million for the second quarter of FY2023 ending June 30 2023, showing a year-on-year increase of 13.5% and 13.0% respectively.
GoodWhale has conducted an extensive analysis of VERTEX PHARMACEUTICALS‘ financials. The findings have determined that VERTEX PHARMACEUTICALS is considered a high risk investment in terms of financial and business aspects. GoodWhale has detected a total of four risk warnings within the income sheet, balance sheet, cashflow statement, and non-financial categories. If you are interested in more details regarding the findings, be sure to register on GoodWhale.com to take a look. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Vertex Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vertex Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vertex Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Vertex Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The competition in the pharmaceutical industry is intense, with companies vying for market share in a constantly changing landscape. Vertex Pharmaceuticals Inc is no stranger to this competition, and its competitors include Nyrada Inc, Incyte Corp, and Gain Therapeutics Inc.
Nyrada Inc is a clinical stage biopharmaceutical company focused on the development of novel therapeutics to treat diseases of the eye, central nervous system and other organ systems. The company’s lead product candidate, NYX-2925, is a small molecule that inhibits the activity of the protein kinase C-beta (PKC-beta) enzyme. NYX-2925 is in clinical development for the treatment of dry eye disease and age-related macular degeneration.
Nyrada’s market cap is $21.06 million and its ROE is -20.85%. The company is focused on the development of novel therapeutics to treat diseases of the eye, central nervous system and other organ systems.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, primarily in oncology.
As of 2022, Incyte Corporation had a market capitalization of $15.48 billion and a return on equity of 9.54%. The company’s main product is Jakafi (ruxolitinib), which is approved for the treatment of myelofibrosis and polycythemia vera, two rare blood disorders. Incyte is also developing several other drugs in clinical trials for various cancers.
– Gain Therapeutics Inc ($NASDAQ:GANX)
Gain Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with serious diseases. The company’s lead product candidate is GT-004, a small molecule inhibitor of the oncogene c-Myc, which is in development for the treatment of solid tumors. Gain Therapeutics has a market cap of $36.13 million and a negative return on equity of 33.26%. The company’s products are still in development and have not yet been approved for sale by the FDA.
Vertex Pharmaceuticals has reported strong financial results for the second quarter of FY2023, with total revenue reaching USD 2493.2 million and net income reaching USD 915.7 million. This represents a year-over-year increase of 13.5% and 13.0% respectively. The figures suggest that investors should take a closer look at Vertex Pharmaceuticals, which may offer a lucrative opportunity.
The company’s strong financial performance and long-term growth potential make it an attractive choice in the pharmaceutical sector. It is worth noting that Vertex Pharmaceuticals has already delivered impressive returns to its shareholders in the past year, so now could be the time to get involved.